Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 14/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030525 | 0.86 | ALDH1A1 (0.54) | CTSBMAPTLMNAMAPK1L3MBTL1 | |
| SCHEMBL27641771 | 0.84 | GAA (0.56) | CTSBMAPTLMNAMAPK1TDP1 | |
| SCHEMBL6197400 | 0.82 | MAPT (0.50) | MAPTLMNAMAPK1KDM4EL3MBTL1 | |
| SCHEMBL6197027 | 0.82 | MAPT (0.50) | MAPTLMNAMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2206983 | 0.78 | CTSB (0.68) | CTSBMAPTLMNAMAPK1TDP1 | |
| SCHEMBL30779614 | 0.78 | CTSB (0.68) | CTSBMAPTLMNAMAPK1TDP1 | |
| SCHEMBL17599744 | 0.76 | ALDH1A1 (0.52) | MAPTLMNAMAPK1TDP1KDM4E | |
| SCHEMBL6199111 | 0.76 | LGMN (0.49) | MAPTLMNAMAPK1KDM4EL3MBTL1 | |
| SCHEMBL14777390 | 0.75 | ALDH1A1 (0.51) | MAPTLMNATDP1KDM4EL3MBTL1 | |
| SCHEMBL28380204 | 0.75 | ALDH1A1 (0.55) | CTSBMAPTLMNAMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
| EP-1130017-B1 | Azole derivatives and their use as superoxide radical inhibitors | OTSUKA PHARMA CO LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-0934937-B1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMA CO LTD (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-RE37556-E1 | (ALKOXYPHENYL)THIAZOLE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1130017-A2 | Azole derivatives and their use as superoxide radical inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6080764-A | PROTECTING VARIOUS TISSUE CELLS FROM DISTURBANCES ASSOCIATED WITH ISCHEMIA AND BLOOD REPERFUSION IN HEART, BRAIN, KIDNEY, LUNG AND DIGESTIVE TRACT BY INHIBITING SUPEROXIDE-RELEASE BY NEUTROPHILIC LEUKOCYTES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| EP-0934937-A1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5677319-A | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| WO-1994014809-A1 | ANELLATED URACIL DERIVATES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1994-07-07 | — | — | WO | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | CTSB 4588/4885MAPT 3318/4885LMNA 4884/4885 |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | CTSB 3587/4885MAPT 4421/4885LMNA 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.